A Phase 3, Randomized, Open-Label, Active-Controlled, Superiority Trial of EG007, Added to the Combination of Lenvatinib Plus Pembrolizumab Vs. Lenvatinib Plus Pembrolizumab in Patients with Advanced Endometrial Cancer
Latest Information Update: 26 Sep 2024
At a glance
- Drugs EG-007 (Primary) ; Lenvatinib (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Endometrial cancer
- Focus Registrational; Therapeutic Use
- Sponsors Evergreen Therapeutics
- 09 Sep 2024 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.
- 09 Sep 2024 Planned primary completion date changed from 1 Dec 2025 to 1 Dec 2026.
- 09 Sep 2024 Planned initiation date changed from 1 Dec 2024 to 1 Dec 2025.